These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 32042344)

  • 21. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Membrane Fusion Liposomes Deliver Antifibrotic and Chemotherapeutic Drugs Sequentially to Enhance Tumor Treatment Efficacy by Reshaping Tumor Microenvironment.
    Jia N; Wang Q; Li W; Chen D; Hu H
    Adv Healthc Mater; 2024 Aug; 13(20):e2400219. PubMed ID: 38657266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model.
    Santana-Krímskaya SE; Franco-Molina MA; Zárate-Triviño DG; Prado-García H; Zapata-Benavides P; Torres-Del-Muro F; Rodríguez-Padilla C
    Biomed Pharmacother; 2020 Jun; 126():110062. PubMed ID: 32172064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
    Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
    J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
    Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.
    Camilio KA; Wang MY; Mauseth B; Waagene S; Kvalheim G; Rekdal Ø; Sveinbjørnsson B; Mælandsmo GM
    Breast Cancer Res; 2019 Jan; 21(1):9. PubMed ID: 30670061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer.
    Wang Y; Chen Y; Ji DK; Huang Y; Huang W; Dong X; Yao D; Wang D
    J Nanobiotechnology; 2024 Aug; 22(1):461. PubMed ID: 39090622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
    Mao C; Li F; Zhao Y; Debinski W; Ming X
    Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Taohong Siwu decoction enhances the chemotherapeutic efficacy of doxorubicin by promoting tumor vascular normalization.
    Cheng Y; Li J; Feng X; Wu Y; Wu X; Lau BWM; Ng SSM; Lee SM; Seto SW; Leung GP; Hu Y; Fu C; Zhang S; Zhang J
    Phytomedicine; 2024 Nov; 134():155995. PubMed ID: 39270591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.
    Evans EE; Jonason AS; Bussler H; Torno S; Veeraraghavan J; Reilly C; Doherty MA; Seils J; Winter LA; Mallow C; Kirk R; Howell A; Giralico S; Scrivens M; Klimatcheva K; Fisher TL; Bowers WJ; Paris M; Smith ES; Zauderer M
    Cancer Immunol Res; 2015 Jun; 3(6):689-701. PubMed ID: 25614511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.
    Kim SS; Harford JB; Moghe M; Slaughter T; Doherty C; Chang EH
    Int J Cancer; 2019 Nov; 145(9):2535-2546. PubMed ID: 31241175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
    Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
    Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A synergistic approach for modulating the tumor microenvironment to enhance nano-immunotherapy in sarcomas.
    Mpekris F; Panagi M; Charalambous A; Voutouri C; Michael C; Papoui A; Stylianopoulos T
    Neoplasia; 2024 May; 51():100990. PubMed ID: 38520790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.